Emergent Biosolutions (NYSE:EBS) Price Target Lowered to $10.00 at HC Wainwright

Emergent Biosolutions (NYSE:EBS) had its price target decreased by investment analysts at HC Wainwright from $12.00 to $10.00 in a research note issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price objective points to a potential upside of 106.31% from the stock’s previous close.

Other analysts have also recently issued research reports about the company. UBS Group reaffirmed a “buy” rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. Benchmark reissued a “buy” rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Emergent Biosolutions in a research note on Friday. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Emergent Biosolutions currently has an average rating of “Hold” and an average price target of $10.00.

Emergent Biosolutions Stock Performance

EBS stock opened at $4.85 on Monday. The company has a debt-to-equity ratio of 1.70, a current ratio of 5.42 and a quick ratio of 2.95. Emergent Biosolutions has a 1-year low of $4.81 and a 1-year high of $14.06. The business has a 50-day moving average price of $7.82 and a 200 day moving average price of $8.75. The company has a market capitalization of $250.09 million, a P/E ratio of -1.37 and a beta of 2.35.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.68. Emergent Biosolutions had a negative net margin of 22.95% and a positive return on equity of 16.35%. The firm had revenue of $234.30 million during the quarter, compared to analysts’ expectations of $177.50 million.

Insider Buying and Selling at Emergent Biosolutions

In related news, SVP Paul Anthony Williams sold 3,000 shares of the business’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $8.40, for a total transaction of $25,200.00. Following the transaction, the senior vice president directly owned 159,098 shares in the company, valued at $1,336,423.20. The trade was a 1.85% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.00% of the stock is owned by insiders.

Institutional Investors Weigh In On Emergent Biosolutions

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Torren Management LLC acquired a new stake in shares of Emergent Biosolutions in the fourth quarter valued at about $37,000. CANADA LIFE ASSURANCE Co purchased a new stake in Emergent Biosolutions during the 4th quarter valued at about $45,000. Legal & General Group Plc acquired a new position in shares of Emergent Biosolutions during the 2nd quarter worth approximately $31,000. Farther Finance Advisors LLC lifted its position in Emergent Biosolutions by 361.3% during the fourth quarter. Farther Finance Advisors LLC now owns 6,163 shares of the biopharmaceutical company’s stock worth $76,000 after buying an additional 4,827 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of Emergent Biosolutions in the 2nd quarter worth $53,000. 78.40% of the stock is currently owned by hedge funds and other institutional investors.

About Emergent Biosolutions

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.